Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar ...
FedEx, the shipping and logistics giant, plans to spin off its freight trucking business, Novo Nordisk sinks after ...
Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback